Summary of Key Information:

Reporting Period: Quarter and Half Year Ended September 30, 2026

Nature of Filing: Outcome of Board Meeting under Regulation 30 and 33 of SEBI LODR

Date of Board Meeting / Approval: November 11, 2026 (12:30 pm to 2:00 pm)

Audit Opinion: Unmodified opinion on both standalone and consolidated financial results

Auditor's Comment: No qualifications or modifications affecting earnings quality

Key Financial Highlights [₹ in Lakhs]

Standalone Results:

Revenue from Operations: Q2 FY27: 8,820.38 (vs Q2 FY26: 7,784.35, +13.3% YoY); H1 FY27: 15,603.35 (vs H1 FY26: 15,688.63, -0.5% YoY)

Total Income: Q2 FY27: 8,837.04; H1 FY27: 15,665.62

Net Profit: Q2 FY27: 431.14 (vs Q2 FY26: 497.77, -13.4% YoY); H1 FY27: 754.92 (vs H1 FY26: 1,013.54, -25.5% YoY)

EPS: Q2 FY27: 14.26; H1 FY27: 24.97

Other Equity: 21,868.94 (vs previous year: 21,155.36)

Cash and Cash Equivalents: 69.22

Debt: Short-term borrowings: 7,137.01; Long-term borrowings: 4,247.06; Total borrowings: 11,384.07

Consolidated Results:

Revenue from Operations: Q2 FY27: 9,138.06 (vs Q2 FY26: 8,136.76, +12.3% YoY); H1 FY27: 16,546.11 (vs H1 FY26: 16,387.23, +1.0% YoY)

Total Income: Q2 FY27: 9,145.95; H1 FY27: 16,599.55

Net Profit: Q2 FY27: 175.96 (vs Q2 FY26: 642.53, -72.6% YoY); H1 FY27: 360.00 (vs H1 FY26: 1,080.74, -66.7% YoY)

Attribution: Q2 FY27 - Equity holders: 325.52, Non-controlling interest: (149.56); H1 FY27 - Equity holders: 590.19, Non-controlling interest: (230.20)

EPS: Q2 FY27: 10.77; H1 FY27: 19.52

Cash and Cash Equivalents: 118.07

Segment-wise Performance:

The company operates in a single reportable business segment - manufacturing of Active Pharmaceutical Ingredients and their intermediates

Corporate Actions:

No dividend declarations, share splits, bonus issues, or buybacks announced

Other Significant Information:

Capital Expenditure:

Significant increase in Capital Work-in-Progress:

  • Standalone: 1,020.26 (vs 130.07 previous year)
  • Consolidated: 3,003.35 (vs 1,042.21 previous year)

Subsidiary Performance:

Mahi Drugs Private Limited (subsidiary) reported:

  • Total revenue: ₹829.59 lakhs for Q2 FY27
  • Net loss after tax: ₹373.91 lakhs for Q2 FY27
  • Total comprehensive loss: ₹371.35 lakhs for Q2 FY27

Related Party Transactions:

Significant transactions with:

  • Mahi Drugs Private Limited: Purchases ₹645.13 lakhs, Sales ₹452.27 lakhs
  • Purogene Labs Private Limited: Purchases ₹881.91 lakhs, Sales ₹164.12 lakhs
  • SMS Pharmaceuticals Ltd: Sales ₹385.03 lakhs
  • ChemWerth Inc. USA: Sales ₹65.67 lakhs
  • Key Management Personnel: Remuneration ₹99.07 lakhs to TVVSN Murthy

Financial Position Changes:

Inventory increased significantly:

  • Standalone: 8,284.38 (vs 6,981.30)
  • Consolidated: 10,563.15 (vs 7,982.42)

Trade receivables increased:

  • Standalone: 6,366.22 (vs 5,426.43)
  • Consolidated: 7,527.12 (vs 6,133.93)

Borrowings increased:

  • Standalone: 11,384.07 (vs 9,310.80)
  • Consolidated: 13,356.65 (vs 10,885.25)

Entities in Consolidation:

Includes financial results of Mahi Drugs Private Limited, a subsidiary

Accounting Policies:

Financial results prepared in accordance with Indian Accounting Standards (Ind AS)

Figures for previous periods reclassified/regrouped where necessary